spacer
home > ebr > spring 2002 > pharmacogenetics and the development of anticancer agents
PUBLICATIONS
European Biopharmaceutical Review

Pharmacogenetics and the Development of Anticancer Agents

The observation that individuals respond differently to the same drug is centuries old, yet only recently has the biological basis for such variation begun to be unravelled. In the field of pharmacogenetics, detailed biological understanding of the pathways by which drugs act and are metabolised, guides high throughput DNA sequencing efforts to reveal variations within genes critical to therapeutic response. Such variance data is used to associate responsiveness to a drug with specific genetic variations, which can then serve as predictive markers to guide drug usage. This article summarises progress in identifying genetic markers that predict the toxicity and efficacy of chemotherapeutic drugs. Several types of markers have been associated with response to a variety of anticancer agents, including DNA polymorphisms, loss of heterozygosity, and RNA expression patterns within tumours. Some genetic features of cancer that provide the basis for these markers are outlined briefly, examples of each type of marker are provided, and the utility of pharmacogenetics throughout the drug development process is discussed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ann E. Ferentz, Senior Scientist and Manager of Scientific Communications at Variagenics, Inc

Ann Ferentz obtained her BS from Yale University and her PhD in Chemistry from Harvard University. Her subsequent research at Harvard Medical School and the Massachusetts Institute of Technology focused on structural biology and cellular responses to DNA damage.
She is currently a Senior Scientist and Manager of Scientific Communications at Variagenics, a pharmacogenomics company in Cambridge, Massachusetts.

spacer
Ann E. Ferentz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Safe’n’Spray™, the smart electronic concept device with child-resistant and locking features, wins the ‘Best Innovation In Drug Delivery Device’ Award at Pharmapack 2020

On February 5th, during the Pharmapack Awards Ceremony, Safe’n’Spray, Nemera’s smart electronic concept device with child-resistant and locking features, was celebrated as the “Best Innovation in Drug Delivery Device”.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement